Magnum Boss Confident Ice Cream Giant Will Thrive Amid Weight-Loss Jab Trend
The chief executive of the world's largest ice cream maker has revealed how the company behind Magnum and Ben & Jerry's plans to navigate the growing popularity of weight-loss medications. Peter ter Kulve, who leads Unilever's ice cream division, stated that while GLP-1 drugs are changing eating habits, they will not eliminate the public's appetite for indulgent treats.
"Mindless Munching" Reduction Presents New Opportunities
Mr ter Kulve acknowledged that GLP-1 medications, which include popular weight-loss injections, are reducing what he called "mindless munching" and binge eating behaviors. However, he emphasized this shift actually creates positive opportunities for the ice cream industry.
"When people are on GLP-1s, they do not stop eating treats," the CEO explained. "You do, however, see a stark reduction of mindless munching and binge eating. People on GLP-1s make more deliberate choices and have more control. This is actually a good thing."
He described how medication users are seeking:
- Smaller portions of their favorite foods
- Fewer calories per serving
- More nutritional density in their snacks
- Real ingredients and higher protein content
Premium Portion-Controlled Products as Strategic Response
The ice cream giant has been actively responding to these changing consumer preferences by expanding its range of portion-controlled options. This includes the bite-size Magnum Bonbon range and Ben & Jerry's Peaces, both designed to meet demand for controlled indulgence.
Mr ter Kulve characterized this shift as a "real opportunity" for the company to provide lower-calorie treats at premium prices. He stressed that Unilever remains "very keen to be part of" creating a healthier society through its product offerings.
Current Impact Limited to US Market
Despite industry concerns about broader impacts on snacking companies, the CEO noted that significant GLP-1 usage is currently concentrated in the United States. He described the "overall impact on the world as small" at present, though the company is preparing for potential wider adoption.
This perspective comes at a time when weight-loss drugs have shaken consumer trends and US political campaigns have emphasized health initiatives. The company's December 2025 stock market listing tested investor appetite for sugar-heavy products amid these changing market conditions.
Confidence in Indulgent Snack Market Resilience
Unilever's ice cream division, which also produces Cornetto and Carte D'or brands, commands more than a fifth of the $87 billion global ice cream market. The company previously announced it is betting on the enduring allure of indulgent snacks despite health trends.
Mr ter Kulve's comments reveal a nuanced corporate strategy that acknowledges changing consumer behaviors while maintaining confidence in the fundamental human desire for treats. The company's approach combines product innovation with premium positioning to navigate evolving market dynamics.
